Immuneering (NASDAQ:IMRX) Upgraded at Cantor Fitzgerald

Immuneering (NASDAQ:IMRX) was upgraded by research analysts at Cantor Fitzgerald to a “strong-buy” rating in a note issued to investors on Wednesday,Zacks.com reports.

Other analysts have also issued research reports about the stock. Chardan Capital reiterated a “buy” rating and issued a $20.00 target price on shares of Immuneering in a research report on Tuesday, May 19th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immuneering in a research note on Wednesday, June 24th. Wall Street Zen cut Immuneering from a “hold” rating to a “sell” rating in a report on Saturday, June 13th. Finally, Oppenheimer reiterated an “outperform” rating on shares of Immuneering in a research note on Monday, June 1st. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $16.57.

Immuneering Price Performance

Immuneering stock opened at $5.53 on Wednesday. The stock has a market capitalization of $357.79 million, a PE ratio of -4.73 and a beta of 0.41. The business has a 50 day simple moving average of $4.86 and a 200-day simple moving average of $5.19. Immuneering has a 12 month low of $2.90 and a 12 month high of $10.08.

Immuneering (NASDAQ:IMRX) last announced its earnings results on Friday, May 15th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.09. On average, equities research analysts anticipate that Immuneering will post -1.12 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Jane Street Group LLC purchased a new stake in shares of Immuneering in the first quarter valued at approximately $32,000. Caitong International Asset Management Co. Ltd acquired a new position in Immuneering during the fourth quarter worth $33,000. Levin Capital Strategies L.P. acquired a new position in Immuneering during the first quarter worth $53,000. Cetera Investment Advisers purchased a new stake in Immuneering in the 1st quarter valued at $67,000. Finally, SummitTX Capital L.P. purchased a new stake in Immuneering in the 4th quarter valued at $69,000. 67.65% of the stock is currently owned by institutional investors and hedge funds.

Immuneering Company Profile

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.